Superworth

Regeneron Pharmaceuticals PE ratio REGN

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Nov 3, 2026
24.0×
10-year median
19.7×
Against its 10-year history
65th
percentile: 0 is its lowest day, 100 its highest
10-year range
8.1× to 62.3×
Peer median
26.7×

Regeneron Pharmaceuticals' PE ratio is 24.0× as of Nov 3, 2026: a share price of $970.82 against $40.44 of earnings per share over the last twelve months.

That is above its ten-year median of 19.7×, higher than on 65% of days in the last ten years.

Over that time it ranged from 8.1× in Jun 2022 to 62.3× in Jun 2017.

The median for 9 biotech stocks of a similar size is 26.7×.

PE ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far23.8×14.9×23.8×
202518.8×12.5×18.8×
202417.6×17.4×32.5×
202325.1×15.2×25.1×
202215.2×8.1×16.2×
202110.1×9.8×19.7×
202017.7×17.5×32.4×
201920.0×13.8×27.5×
201823.2×21.8×35.0×
201734.1×33.9×62.3×
201654.4×50.6×95.8×
2015106×104×176×
2014140×38.7×144×
201339.5×24.3×92.9×
201286.1×72.2×92.8×

Against its peers

Companies in Biotechnology nearest Regeneron Pharmaceuticals' size, closest first, today.

CompanyPE ratio
REGNRegeneron Pharmaceuticals24.0×
VRTXVertex Pharmaceuticals31.5×
ONCBeOne Medicines63.2×
UTHRUnited Therapeutics21.6×
INCYIncyte15.3×
ALNYAlnylam Pharmaceuticals26.7×
EXELExelixis22.1×
NBIXNeurocrine Biosciences21.3×
HALOHalozyme Therapeutics38.5×
TECHBIO-TECHNE63.2×
Peer median26.7×

Where Regeneron Pharmaceuticals ranks

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Regeneron Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.